Your browser doesn't support javascript.
loading
Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Hirbe, Angela C; Dehner, Carina A; Dombi, Eva; Eulo, Vanessa; Gross, Andrea M; Sundby, Taylor; Lazar, Alexander J; Widemann, Brigitte C.
Affiliation
  • Hirbe AC; Division of Oncology, Department of Medicine, Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St Louis, MO.
  • Dehner CA; Department of Anatomic Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN.
  • Dombi E; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Eulo V; Division of Oncology, Department of Medicine, University of Alabama, Birmingham, AL.
  • Gross AM; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Sundby T; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Lazar AJ; Departments of Pathology & Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Widemann BC; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Am Soc Clin Oncol Educ Book ; 44(3): e432242, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38710002
ABSTRACT
Most malignant peripheral nerve sheath tumors (MPNSTs) are clinically aggressive high-grade sarcomas, arising in individuals with neurofibromatosis type 1 (NF1) at a significantly elevated estimated lifetime frequency of 8%-13%. In the setting of NF1, MPNSTs arise from malignant transformation of benign plexiform neurofibroma and borderline atypical neurofibromas. Composed of neoplastic cells from the Schwannian lineage, these cancers recur in approximately 50% of individuals, and most patients die within five years of diagnosis, despite surgical resection, radiation, and chemotherapy. Treatment for metastatic disease is limited to cytotoxic chemotherapy and investigational clinical trials. In this article, we review the pathophysiology of this aggressive cancer and current approaches to surveillance and treatment.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurofibromatosis 1 / Nerve Sheath Neoplasms Limits: Humans Language: En Journal: Am Soc Clin Oncol Educ Book Year: 2024 Document type: Article Affiliation country: Macao

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neurofibromatosis 1 / Nerve Sheath Neoplasms Limits: Humans Language: En Journal: Am Soc Clin Oncol Educ Book Year: 2024 Document type: Article Affiliation country: Macao